PAE5 Antibody

Introduction to SpA5 Antibody

SpA5 Antibody (e.g., Abs-9) is a human immunoglobulin G (IgG) developed to neutralize Staphylococcus aureus infections by targeting the pentameric form of Protein A (SpA5), a virulence factor aiding bacterial immune evasion . This antibody was identified through high-throughput single-cell RNA and VDJ sequencing of memory B cells from vaccinated individuals .

Antibody Structure

• Format: IgG1 subclass with a conventional Y-shaped structure comprising two heavy (VH) and two light (VL) chains .

• Paratope: Complementarity-determining regions (CDRs) in the Fab fragment mediate antigen binding, with CDRH3 contributing significantly to SpA5 affinity .

• Affinity: Exhibits a dissociation constant ($K_D$) of $1.959 \times 10^{-9}$ M, measured via Biolayer Interferometry .

Epitope Specificity

• Binds to the N847-S857 epitope on SpA5, validated through molecular docking and AlphaFold2 predictions .

• Demonstrates no cross-reactivity with non-target antigens in mass spectrometry assays .

Preclinical Efficacy

Mechanism of Action

1. Neutralization: Blocks SpA5-mediated inhibition of phagocytosis and B-cell receptor signaling .

2. Opsonization: Fc region recruits macrophages and neutrophils via Fcγ receptors .

Clinical Relevance

• Phase III Trials: Part of the recombinant five-component S. aureus vaccine (rFSAV), showing prophylactic efficacy in early-phase trials .

• Therapeutic Potential: Targets antibiotic-resistant MRSA strains by disrupting immune evasion mechanisms .

Comparative Analysis of Antibody Engineering Strategies

Challenges and Future Directions

• Scalability: High-throughput sequencing and recombinant production require optimization for large-scale manufacturing .

• Resistance Monitoring: Continuous surveillance for SpA5 mutations to maintain therapeutic efficacy .